Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease

Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease

US Patent 9840710 · Granted Dec 12, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antisense compounds targeting genes associated with cystic fibrosis2024
Compounds and methods for the modulation of amyloid-β precursor protein2023
Antisense compounds targeting genes associated with cystic fibrosis2021
Glucocerebrosidase gene therapy for Parkinson's disease2021
Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatm2020
Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatm2020
Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatm2020
Antisense compounds targeting genes associated with cystic fibrosis2020
Antisense compounds targeting genes associated with cystic fibrosis2020
Antisense compounds targeting apolipoprotein E receptor 22019
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treat2019
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treat2019